Browse Penn-owned technologies available for licensing.
Dr. Greene and his colleagues have developed a new class of small molecules that selectively inhibit Her2 activity, leading to a targeted therapy against Her2-related cancer. This new class of Her2 inhibitors target the extracellular domain of the receptor and offer an alternative treatment for patients developing resistance to current tyrosine kinase inhibitors. They are also potential oral compounds as they are small molecules.
In addition, these molecules can be labeled with imaging agent to monitor Her2-expresssing tumors in vivo. The discovered molecules, which are attainable for oral administration, can be used alone or in combination with cytotoxic drugs, hormonal agent, radiation, or other Her2 inhibitors to treat breast, lung, prostate, and other Her2-associated cancers.